Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Warty, you've been here at least as long as I have, so you must know the drill by now. No news = death by a thousand cuts. It was ever thus. 33% - 50% retracements have been the order of the day for as long as I can remember. 0.9p down to 0.6p; 2p down to 1p; 3p down to 1.5p; and now 10p down to 5p (more or less), and that's off the top of my head since roughly 2015. I've even been down 70% at one point!! But I held, mainly because I was convinced the science was ground-breaking, and I also realized that biotech takes time. You seem like a "glass half empty" kind of guy, which is a shame. Try to see the positives here, of which there are many. But for me, SDC-1801 outperforming dexamethasone and equalling baricitinib (and, so far, without the toxicity issues) is massive. Add to that the various patent protections, SRA 737 looking like a go in combo trials, and SDC-1802 in cancer promising much, what's not to like? This year, next year, 2021, 2022, who gives a flying monkey's? Give it time and ignore the noise. AIMHO, of course. Each to their own, etc.
Seems like my math wasn't so bad, after all!
...in my humble opinion. It feels like we're being played. Another 250K gone through at full ask. Only just over 1% of shares in issue traded so far (and over one third of those are buys!!) and we're currently down over 6%. My math was never good, but that seems overdone, but I could be wrong lol!
Ask Lucky. He knows all about bear raids!
'Rise and shine - 29.' Bingo call. Here's hoping.
glaw, are you aware of the cost of cutting edge oncology drugs?
(18 Oct 2021 08:30) "Never...
Buy or sell in first hour. It will be a bit tipsy turvy today I think."
Bet you wish you had sold first thing this morning!
(02 Nov 2021 08:10) "Val...
I can see some money coming out of here [SAR] and into val today unfortunately, could be big over there today".
No kidding, Utah. It's been humungous!
I think he was talking USD, not GBP, with the $4 billion figure? So I think it's correct.
I don't really have an opinion, one way or the other, although I do tend to shy away from companies with billions of shares in issue (SAR obviously being the exception). It's irrational, I know, but it's also perhaps psychological. I did, however, take a keen interest in two companies' share consolidations. One was OXB, back in 2018, and the other more recently, RMM. For RMM, it's been a disaster of sorts, but not necessarily due to the consolidation. But for OXB, it's been a boon. This from their May, 2018 RNS, announcing the proposed consolidation: "The Board considers the Consolidation to be in the best interests of the Company and its Shareholders. It believes that the effect of the Consolidation will be to improve market liquidity by reducing the volatility and spread of trading activity in the Company's New Consolidated Ordinary Shares and make trading in the Company's shares more attractive to a broader range of institutional investors and other members of the investing public, both overseas and in the UK." OXB decided on a 50 to 1 ratio. The day of consolidation the SP went from 15p to 750p (actually finishing at 700p). Not wonderful, I hear you cry! But yesterday's close was 1522p ("double your money, double your fun"). I just see similarities here - 2 cutting edge biotech companies with products/IP of great interest to the larger pharmaceuticals. Credibility is key to selling oneself to the big players. Does a company operating out of a glorified garden shed in some Cambridge backwater, with 3.5 billion shares in issue, inspire confidence? IMO, a resounding "Yes!", but do the likes of GSK, AZ, Merck, etc. share my enthusiasm? Just my Saturday musing, but could the addition of PH be, indeed, to effect a share consolidation? Discuss.
For anyone interested, just a clarification of the role of the corporate broker.
"The key services that brokers provide quoted companies with include:
• Pure broking services, which comprise all market making and equity-raising activities for quoted company clients, such as successfully issuing equity (company shares) and supporting the equity issues with the broker’s in-house underwriting capabilities
• Providing support services such as disseminating market intelligence to clients, supporting them during results announcements, assisting with investor relations and performing shareholder analysis
• Serving as the interface with regulators, e.g. AIM Regulation (in a Nominated Adviser capacity), the UK Listing Authority (UKLA) and the Takeover Panel, as appropriate
• Advising the company on the market aspects of transactions, such as the likely market response to an M&A transaction."
Mention of takeover panels and M&A transactions certainly gets the pulse racing (or maybe I've just had too much coffee this morning!). GLA.
Alan, I did the same just before the revelations re: Matt Han**** became news. I truly believe Sareum were in the government's crosshairs at that time, but Han****'s resignation changed everything. I felt that Sajid Javid would probably want to distance himself from his predecessor, at least initially, hence the seemingly interminable wait regarding AGILE. So your email is timely - good job. Let's hope there are no new scandals surrounding SJ!
Ralphie, I agree, these double digit trades are perplexing. Until, of course, you see them as bingo calls/'in the know' messages between the MMs. In which case, 31 means "Get up and run", which might seem appropriate, given the SP has been on its knees for a while now. I remain confident, and see current levels as a tremendous buying opportunity, but DYOR (as always). Good luck everyone.
Strean, within 7 minutes you posted two comments expressing the same thing i.e. no news for 3 weeks, "back to watching paint dry". I actually think the next two weeks will be very revealing. But it's your veiled attempt to sow doubt which I find a bit pathetic. You're dealing with a bulletin board full of LTHs with extremely sticky fingers. We've seen people like you come and go, usually just before significant news. But you think we'll all sell up just because you predict the SP will fall and because there will be no news for 3 weeks? That's why I said you're barking and that's why I think you're wrong.
Strean, you're barking up the wrong tree old boy!
"Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclosed to the market." This suggests they will have to tread very carefully. In discussions?
Perhaps merely a coincidence, but Scancell have today announced that it has expanded its R&D capabilities with new facilities at The Oxford Science Park, where Physiomics are also based. 'Professor Lindy Durrant, Chief Executive Officer, Scancell, said: "TOSP is the perfect location for Scancell's expansion, with access to an excellent local talent pool as we grow the business. We are excited to be part of the creative and collaborative group of companies located in the Park and look forward to further developing our innovative products at this new site."' Scancell, for anybody unfamiliar with the company, is a developer of novel immunotherapies for the treatment of cancer and infectious disease. It would seem like a good fit for both SCLP and PYC, but I could be completely barking. Thoughts anyone?
...it's good to dream! I, for one, admire your optimism. GLA, whatever your 'I can now retire' exit price might be.
I'm gutted for them lol! As for Jolly Speculator's target price of 4.9p, dream on! It's a bit like the SAR board here. When the naysayers turn up, predicting doom and gloom, it's a sure sign we're on the up. So predictable. Good day yesterday. Let's hope we can maintain the momentum. As Kidlington says, with so few shares in free float, this can move up very rapidly. GLA.
https://www.cityam.com/government-buys-100000-doses-of-covid-antibody-treatment/
'Health and social care secretary Sajid Javid said: “This latest deal further reflects the UK’s fantastic track record for finding the world’s best Covid-19 treatments – for example, dexamethasone, which has saved tens of thousands of lives in England alone.
We’ve signed the contract for this novel and promising Covid-19 treatment to strengthen our armoury of therapeutics and to ensure it can be rolled out to patients as quickly as possible, should it be approved by our medicines regulator. While the vaccination programme continues to protect millions, it’s vital we keep securing the most cutting-edge treatments for this disease to protect as many people as possible for years to come.”'
Of course, our SDC-1801 was considered superior to Dexamethasone. Strengthening the UK's "armory of therapeutics" promises more to come. And finally, "securing cutting-edge treatments" - sounds familiar? Feels like we're on the cusp.
Copy that. All best.